WO2004034972A3 - Compounds, compositions, and methods - Google Patents

Compounds, compositions, and methods Download PDF

Info

Publication number
WO2004034972A3
WO2004034972A3 PCT/US2003/030788 US0330788W WO2004034972A3 WO 2004034972 A3 WO2004034972 A3 WO 2004034972A3 US 0330788 W US0330788 W US 0330788W WO 2004034972 A3 WO2004034972 A3 WO 2004034972A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
compounds
methods
ksp
modulating
Prior art date
Application number
PCT/US2003/030788
Other languages
French (fr)
Other versions
WO2004034972A2 (en
Inventor
Gustave Bergnes
David J Morgans Jr
Original Assignee
Cytokinetics Inc
Gustave Bergnes
David J Morgans Jr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc, Gustave Bergnes, David J Morgans Jr filed Critical Cytokinetics Inc
Priority to AU2003277079A priority Critical patent/AU2003277079A1/en
Priority to US10/529,745 priority patent/US7557115B2/en
Priority to JP2004544787A priority patent/JP2006501306A/en
Priority to EP03808978A priority patent/EP1558083A4/en
Publication of WO2004034972A2 publication Critical patent/WO2004034972A2/en
Publication of WO2004034972A3 publication Critical patent/WO2004034972A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds, compositions and methods useful for treating cellular proliferative diseases and disorders, for example, by modulating the activity of KSP, are disclosed.
PCT/US2003/030788 2002-09-30 2003-09-30 Compounds, compositions, and methods WO2004034972A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003277079A AU2003277079A1 (en) 2002-09-30 2003-09-30 Compounds, compositions, and methods
US10/529,745 US7557115B2 (en) 2002-09-30 2003-09-30 Compounds, compositions, and methods
JP2004544787A JP2006501306A (en) 2002-09-30 2003-09-30 Compounds, compositions and methods
EP03808978A EP1558083A4 (en) 2002-09-30 2003-09-30 Compounds, compositions, and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41475602P 2002-09-30 2002-09-30
US60/414,756 2002-09-30

Publications (2)

Publication Number Publication Date
WO2004034972A2 WO2004034972A2 (en) 2004-04-29
WO2004034972A3 true WO2004034972A3 (en) 2004-11-25

Family

ID=32107876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/030788 WO2004034972A2 (en) 2002-09-30 2003-09-30 Compounds, compositions, and methods

Country Status (5)

Country Link
US (1) US7557115B2 (en)
EP (1) EP1558083A4 (en)
JP (1) JP2006501306A (en)
AU (1) AU2003277079A1 (en)
WO (1) WO2004034972A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166595B2 (en) 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
US7345046B2 (en) 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
DK1689724T3 (en) 2003-11-25 2012-02-27 Novartis Ag Quinazolinone compounds as anticancer agents
US7485666B2 (en) * 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
MXPA06014909A (en) * 2004-06-18 2007-02-28 Chiron Corp N- (1- (1-benzyl -4-phenyl-1h-imidazol-2-yl) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (ksp) inhibitors for the treatment of cancer.
UY29070A1 (en) 2004-08-18 2006-03-31 Astrazeneca Ab FUSIONED HETEROCYCLIC ENANTIOMERS AND THEIR USES
WO2006026597A2 (en) * 2004-08-30 2006-03-09 Smithkline Beecham Corporation Novel compositions and methods of treatment
WO2007044724A2 (en) * 2005-10-06 2007-04-19 Exelixis, Inc. Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3
JP5019768B2 (en) * 2006-03-23 2012-09-05 独立行政法人科学技術振興機構 Novel low molecular weight compound and method for producing the same
EP2079739A2 (en) 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
CA2797872A1 (en) * 2010-05-21 2011-11-24 Gilead Sciences, Inc. Heterocyclic flaviviridae virus inhibitors
UY35675A (en) 2013-07-24 2015-02-27 Novartis Ag SUBSTITUTED DERIVATIVES OF QUINAZOLIN-4-ONA
RU2745788C2 (en) * 2016-08-05 2021-03-31 Басф Се Macromonomers containing polyisobutene groups and their homo- and copolymers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009036A2 (en) * 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1249281B (en) * 1963-05-18
US3320124A (en) * 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
BG16042A3 (en) 1968-11-12 1972-05-20 Nans Ott METHOD FOR OBTAINING NEW 2(1H)-QUINAZOLINONES
US3962244A (en) * 1971-01-23 1976-06-08 Hoechst Aktiengesellschaft Benzene sulfonyl ureas
US3740442A (en) * 1972-01-14 1973-06-19 Sandoz Ag 2-isopropylaminobenzophenones in treating inflammation
US4011324A (en) * 1976-01-20 1977-03-08 Pfizer Inc. Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents
US4281127A (en) * 1979-07-09 1981-07-28 Hoffmann-La Roche Inc. Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives
DE3177130D1 (en) 1980-08-30 1990-01-11 Hoechst Ag AMINO ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, MEANS CONTAINING THEM AND THE USE THEREOF.
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
DE3609598A1 (en) * 1986-03-21 1987-10-01 Hoechst Ag 2-AZOLYLMETHYL-2-ARYL-1,3-DIOXOLANE AND THE SALTS THEREOF, METHOD FOR THE PRODUCTION THEREOF, MEANS CONTAINING IT AND THEIR USE
GB8607683D0 (en) * 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US5187167A (en) * 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
US4729996A (en) 1986-05-29 1988-03-08 Harbor Branch Oceanographic Institution, Inc. Antitumor compositions and their methods of use
GB8707053D0 (en) * 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
US4808590A (en) * 1987-07-17 1989-02-28 Harbor Branch Oceanographic Institution, Inc. Antiviral, antitumor and antifungal compositions and their methods of use
US4866084A (en) * 1987-07-17 1989-09-12 Harbor Branch Oceanographic Institution, Inc. Topsentin compounds effective against viruses and certain tumors
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US4857530A (en) * 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
GB8827820D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US4970226A (en) 1989-10-03 1990-11-13 Harbor Branch Oceanographic Institution, Inc. Bis-indole imidazole compounds which are useful antitumor and antimicrobial agents
US5264439A (en) 1990-02-13 1993-11-23 Merck & Co., Inc. Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element
IL98167A0 (en) 1990-05-30 1992-06-21 Ici Plc Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them
FR2665159B1 (en) * 1990-07-24 1992-11-13 Rhone Poulenc Sante NEW PYRIDINE AND QUINOLEIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
EP0481614A1 (en) * 1990-10-01 1992-04-22 Merck & Co. Inc. Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists
GB9105771D0 (en) * 1991-03-19 1991-05-01 Cancer Res Inst Royal Anti-cancer compounds
US5714493A (en) * 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5316906A (en) * 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
US5204354A (en) * 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
GB9205907D0 (en) 1992-03-18 1992-04-29 Cancer Res Inst Royal Anti-cancer compounds
US5430148A (en) * 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
US5817662A (en) 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5804584A (en) * 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
AU6087894A (en) * 1993-01-14 1994-08-15 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
AU6092794A (en) * 1993-01-19 1994-08-15 Cell Therapeutics, Inc. Oxime-substituted therapeutic compounds
US5574057A (en) 1993-02-03 1996-11-12 University Of Utah Research Foundation Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent
US5837703A (en) 1993-03-31 1998-11-17 Cell Therapeutics, Inc. Amino-alcohol substituted cyclic compounds
US5342944A (en) * 1993-07-19 1994-08-30 American Cyanamid Company Process for the preparation of 2-alkyl-3,5,6,7- or 8-substituted-4(3H)-quinazolinones
US20020198326A1 (en) 1993-11-12 2002-12-26 Taizo Aoyama Polyolefin resin composition
CA2113229C (en) * 1994-01-11 1999-04-20 Mark Pines Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
WO1995019171A1 (en) * 1994-01-14 1995-07-20 Cell Therapeutics, Inc. Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
CA2183562A1 (en) * 1994-02-18 1995-08-24 J. Peter Klein Intracellular signalling mediators
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5801182A (en) * 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
JPH09165385A (en) * 1994-08-26 1997-06-24 Kyowa Hakko Kogyo Co Ltd Quinazoline derivative
US5891879A (en) * 1994-08-31 1999-04-06 Hadasit Medical Research Services & Development Co., Inc. Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
US5753664A (en) * 1995-03-16 1998-05-19 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
US6245768B1 (en) * 1995-06-05 2001-06-12 Neurogen Corporation 1-(N′-(arylalkylaminoalkyl)) aminoisoindoles; a new class of dopamine receptor subtype specific ligands
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
KR100263434B1 (en) 1995-08-30 2000-08-01 오쓰카 요시미쓰 Process for producing quinazolin-4-one derivatives
US5783577A (en) * 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
DE19546918A1 (en) * 1995-12-15 1997-06-19 Bayer Ag Bicyclic heterocycles
DE19615262A1 (en) * 1996-04-18 1997-10-23 Bayer Ag Hetero-linked phenylglycinolamides
US6008010A (en) 1996-11-01 1999-12-28 University Of Pittsburgh Method and apparatus for holding cells
US5852024A (en) 1997-02-11 1998-12-22 Hadasit Treatment and prevention of adhesions
US5948775A (en) * 1997-03-19 1999-09-07 American Home Products Corporation 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones
US6627755B1 (en) * 1997-06-09 2003-09-30 Pfizer Inc Quinazolin-4-one AMPA antagonists
US5939421A (en) * 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
EP1049475A4 (en) * 1998-01-08 2003-06-04 Univ California KINESIN MOTOR MODULATORS DERIVED FROM THE MARINE SPONGE $i(ADOCIA)
US6214879B1 (en) 1998-03-24 2001-04-10 Virginia Commonwealth University Allosteric inhibitors of pyruvate kinase
DE60031285T2 (en) * 1999-08-27 2007-08-30 Chemocentryx Inc., Mountain View HETEROCYCLIC COMPOUNDS AND METHOD FOR MODULATING CXCR3 FUNCTION
US6156758A (en) 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
EP1216234B1 (en) * 1999-09-16 2004-12-29 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6380205B1 (en) * 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6476041B1 (en) * 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6495561B2 (en) * 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US7115653B2 (en) * 2000-03-30 2006-10-03 Curis, Inc. Small organic molecule regulators of cell proliferation
US6613798B1 (en) * 2000-03-30 2003-09-02 Curis, Inc. Small organic molecule regulators of cell proliferation
SI2223922T1 (en) * 2000-04-25 2016-04-29 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US20020165221A1 (en) 2000-10-13 2002-11-07 Baxter Anthony David Mediators of hedgehog signaling pathways, compositions and uses related thereto
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
EP1343505A1 (en) 2000-12-11 2003-09-17 Tularik Inc. Cxcr3 antagonists
DE60208186T2 (en) * 2001-04-09 2006-08-24 Ortho-Mcneil Pharmaceutical Research Inc. CHINAZOLIN AND CHINAZOLE-RELATED COMPOUNDS FOR THE TREATMENT OF INTEGRIN-MEDIATED DISEASES
US20030096813A1 (en) * 2001-04-20 2003-05-22 Jingrong Cao Compositions useful as inhibitors of GSK-3
US7365199B2 (en) * 2001-04-20 2008-04-29 Fujifilm Corporation Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound
US6794379B2 (en) * 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
US6596723B1 (en) * 2001-07-16 2003-07-22 Essential Therapeutics, Inc. Fungal efflux pump inhibitors
AU2002322585A1 (en) * 2001-07-20 2003-03-03 Adipogenix, Inc. Fat accumulation-modulating compounds
EP1434584A2 (en) * 2001-09-05 2004-07-07 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
DE60236605D1 (en) * 2001-09-05 2010-07-15 Minerva Biotechnologies Corp COMPOSITIONS AND ITS USE FOR THE TREATMENT OF CANCER
WO2003043961A2 (en) * 2001-11-19 2003-05-30 Iconix Pharmaceuticals, Inc. Modulators of rho c activity
AU2002346471A1 (en) * 2001-11-20 2003-06-10 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
US7009049B2 (en) * 2002-02-15 2006-03-07 Cytokinetics, Inc. Syntheses of quinazolinones
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20030158188A1 (en) * 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
EP1553931A4 (en) * 2002-05-09 2006-08-30 Cytokinetics Inc Compounds, compositions, and methods
US7166595B2 (en) * 2002-05-09 2007-01-23 Cytokinetics, Inc. Compounds, methods and compositions
AU2003265242A1 (en) * 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
EP1556357A4 (en) * 2002-06-14 2006-09-13 Cytokinetics Inc Compounds, compositions, and methods
US20040092561A1 (en) * 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
EP1539180A4 (en) * 2002-08-21 2006-08-30 Cytokinetics Inc Compounds, compositions, and methods
JP4977837B2 (en) * 2003-09-10 2012-07-18 アイカジェン， インコーポレイテッド Fused ring heterocycles as potassium channel modulators
DK1689724T3 (en) * 2003-11-25 2012-02-27 Novartis Ag Quinazolinone compounds as anticancer agents
US20050152940A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004009036A2 (en) * 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] 2004, BERGNES ET AL: "Preparation of quinazolinone-like derivatives to treat cellular proliferative diseases", XP002903247, accession no. STN Database accession no. 2004:80465 *
See also references of EP1558083A4 *

Also Published As

Publication number Publication date
AU2003277079A1 (en) 2004-05-04
US20060264449A1 (en) 2006-11-23
EP1558083A2 (en) 2005-08-03
JP2006501306A (en) 2006-01-12
EP1558083A4 (en) 2008-04-16
WO2004034972A2 (en) 2004-04-29
AU2003277079A8 (en) 2004-05-04
US7557115B2 (en) 2009-07-07

Similar Documents

Publication Publication Date Title
WO2004018058A3 (en) Compounds, compositions, and methods
WO2003094839A3 (en) Pyrimidinone compounds, compositions and methods
WO2003088903A3 (en) Compounds, compositions, and methods
WO2003103575A3 (en) Compounds, compositions, and methods
WO2004009036A3 (en) Compounds compositions and methods
WO2006113432A3 (en) Compounds, compositions and methods
WO2005107762A3 (en) Certain chemical entities, compositions, and methods
WO2004098494A3 (en) Compounds, compositions, and methods
NO20052267L (en) Compounds, Preparations and Methods
WO2007056143A3 (en) Certain chemical entities, compositions, and methods
WO2007056469A3 (en) Certain chemical entities, compositions, and methods
WO2003082208A8 (en) Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
WO2007056078A3 (en) Certain chemical entities, compositions, and methods
HK1053837A1 (en) Methods and compositions utilizing quinazolinones
WO2004006865A3 (en) Compounds, compositions, and methods
WO2004034972A3 (en) Compounds, compositions, and methods
WO2005046588A3 (en) Compounds, compositions, and methods
WO2004064741A3 (en) Compounds, compositions, and methods
WO2004026226A3 (en) Compounds, compositions and methods
WO2004100873A3 (en) Compounds, compositions, and methods
WO2005042697A3 (en) Compounds, compositions and methods
WO2004024086A3 (en) Compounds, compositions and methods
WO2004032879A3 (en) Compounds, compositions, and methods
WO2005062847A3 (en) Compounds, compositions and methods
WO2005005382A3 (en) Compounds, compositions and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004544787

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003808978

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003808978

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006264449

Country of ref document: US

Ref document number: 10529745

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10529745

Country of ref document: US